CT-INDUSTRIAL-FLOW
18.10.2021 13:08:11 CEST | Business Wire | Press release
Leading industrial pumping solutions provider Industrial Flow Solutions ™, headquartered in New Haven, Conn., USA, announced today the agreement to acquire Clearwater Controls Ltd. ™, based in Glasgow, Scotland. Clearwater Controls offers a broad line of wastewater solutions, beginning with its leading deragging intelligent systems to solve specific pumping problems, to more advanced monitoring technology to optimize and manage entire water networks. Terms of the acquisition were not disclosed. Clearwater Controls will retain its company name and brand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005200/en/
Clearwater Controls is known worldwide for the DERAGGER ™+ line of intelligent deragging control systems. The company is bringing the Internet of Things (IoT) to industry sectors with its newest innovation: cloud-based data analytics and management for improved monitoring of water networks.
Clearwater Controls’ solutions allow engineers and operators to analyze and create baseline data on the performance of their pump networks in real time to optimize operations, identify problems, perform money-saving predictive maintenance, and avoid potentially harmful and costly environmental impacts. These smart interventions will transform the industry from its historic reactive approach to a predictive asset management model.
Incorporating Clearwater Controls’ DERAGGER PRO pump station controller across its brands will bring intelligent efficiency to nearly all product lines of Industrial Flow Solutions, particularly the innovative OverWatch™ Direct In-Line Pumping System platform. Clearwater Controls’ complementary products and technology will provide greater value to customers seeking to reduce startup time, strengthen reliability and provide real-time cloud-based data.
“As technology and smart data bring new changes to the water industry, this acquisition will establish Industrial Flow Solutions and Clearwater Controls as leaders in the new digital revolution,” said John Wilson, President of Industrial Flow Solutions. “This new partnership supports our combined missions to transform any industry that relies on high usage of water and the need for treatment,“ he added.
Wilson expects a dramatic increase in Clearwater Controls’ business as it develops a greater product range for the DERAGGER+ and expands its global customer base.
“This acquisition is of mutual benefit to both companies, making each uniquely more competitive. We have common values of being customer focused, highly responsive, innovative, collaborative, supportive, and ambitious,” Wilson said. “We will provide Clearwater Controls with resources and expertise to strengthen its business overall. Reciprocally, Clearwater Controls’ unique and agnostic control solutions open a huge opportunity for Industrial Flow Solutions to access a worldwide market,” Wilson added.
“Clearwater Controls is taking the lead in seizing the groundswell of interest and momentum around intelligent monitoring and management of wastewater networks,” said Simon Crompton, Managing Director, Clearwater Controls. “Our partnership with Industrial Flow Solutions provides us with a greater footprint to advance pumping technology worldwide,” said Crompton.
About Industrial Flow Solutions
Industrial Flow Solutions specializes in the design, manufacturing, sales and service of pumping and fluid management solutions for harsh, rugged environments. With OverWatch™ direct in-line pump systems, BJM Pumps® products and Stancor® Pumps and Controls, the company offers a comprehensive portfolio of submersible and direct in-line pumps and controls ideal for industrial, commercial and municipal wastewater applications. Industrial Flow Solutions, headquartered in New Haven, Conn., is a portfolio company of May River Capital , a Chicago-based private-equity firm focused on lower middle-market industrial growth companies. For more information, please visit https://flowsolutions.com .
About Clearwater Controls Ltd.
Clearwater Controls launched in 2009 as the research and development division of ID Systems. The company has conceived, developed, and delivered a suite of intelligent pump monitoring and anti-ragging solutions, built around its unique and patented technology. Based in Glasgow, Scotland, United Kingdom, with a rapidly expanding operation in the United States, Clearwater Controls delivers solutions to clients across the UK, Ireland, Continental Europe, and North America. For more information, please visit https://clearwatercontrols.co.uk .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005200/en/
Link:
Social Media:
https://www.facebook.com/Industrial-Flow-Solutions-102601071895549
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom